Kornimate/medical-research-clean huggingface dataset:
status of dental care practices in patients with hereditary angioedema

Conditions: Angio Edema Hereditary

Summary: hereditary angioedema (hae) is a rare genetic disease, it can occur at any age and evolves in flare-ups. these are subcutaneous or submucosal edemas responsible for tightness and pain. all areas can be reached. in addition, all their life, patients have an unpredictable risk of death from asphyxiating angioedema (25% mortality in the absence of specific treatment). surgical procedures, endoscopies and dental procedures can trigger laryngeal ae. thus, the national reference center for angioedema (creak) and the latest international consensus1 recommend that all these procedures be preceded by short-term prophylaxis. the reference treatment is the c1 inhibitor 2 concentrate. but to date, there is no prospective study that has demonstrated the effectiveness of this short-term prophylaxis before dental treatment. only a retrospective study has shown that its implementation made it possible to reduce the risk of crisis by 42% after tooth extraction 3 and that the risk of crisis was greatest within 8 hours following tooth extraction. the c1 inhibitor concentrate must be administered ivl by a nurse within 6 hours before the procedure and therefore implies, in addition to its high cost (1500 €), an organizational burden for the patient who must plan for the passage of an ide, the availability of the product and this sometimes for a simple dental treatment. these constraints have two consequences for dental care: patients avoid going to the dentist to the detriment of their dental health or do not take prophylaxis with the risk of a fatal attack.


Eligibility criteria:
inclusion criteria: * patient with hae with or without c1 inhibitor deficiency * patient over 18 years old exclusion criteria: * patient opposed to the use of their data or refusing to answer the questionnaire * adult patients protected by law

Keywords: prophylaxis dental procedures
lung ultrasound in the evaluation of pneumothorax size

Conditions: Pneumothorax

Summary: background * assessment of the percentage of lung collapse is crucial in the therapeutic decision-making of pneumothorax. * the methods normally used to this purpose are radiological. computerized tomography scan (ct) is highly accurate because it allows the exact evaluation of the volume of the air layer. however, in clinical practice assessment of the volume of pneumothorax mainly relies on the measurement of the inter-pleural distance at conventional chest radiography (cxr). this latter method is inaccurate. * lung ultrasound is a new method highly accurate in the first diagnosis of pneumothorax, with a sensitivity superior to cxr and similar to ct in case of traumatic pneumothorax. * the scientific community is actually debating about the usefulness of lung ultrasound in the quantification of pneumothorax \[\]. lung ultrasound can assess the superficial extension of the pneumothorax, but cannot evaluate its volume. aim * main purpose of the study is to compare measurement of the superficial extension of pneumothorax on the chest wall obtained by lung ultrasound, to the evaluation of the air volume performed by ct in patients with pneumothorax. * the main hypothesis of the study is that the cut-off between small (\ 11% of lung collapse) pneumothorax can be identified by a lung ultrasound evaluation of the superficial extension of pneumothorax. * second purpose of the study is to compare the accuracies of lung ultrasound and cxr in predicting the volume of pneumothorax assessed by ct. * secondary hypothesis is that lung ultrasound demonstrates greater accuracy in the prediction of volume of pneumothorax and percentage of lung collapse. methods * patients with a diagnosis of pneumothorax confirmed at ct are prospectively enrolled and submitted to lung ultrasound within 20 min from the ct study. * different locations of the sonographic "lung point" on the chest wall (i.e. the point on the chest wall where the sonographic pattern of the normally aerated lung alternates with the pathologic sonographic pattern of pneumothorax) are compared with different volumes of pneumothorax measured by ct.


Eligibility criteria:
inclusion criteria: * radiologic diagnosis of pneumothorax * clinical need to perform a ct scan * ability to perform the lung ultrasound imaging within 20 minutes from the ct study exclusion criteria: * age less than 16 years

Keywords: pneumothorax lung ultrasound chest sonography
role of mri in breast cancer subtypes

Conditions: MRI in Breast Cancer

Summary: efficacy of mri in detection of breast cancer molecular subtypes instead of biopsy and immunohistochemistry

2.4.4 -study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): patient with breast cancer (malignant breast mass) will do mri breast and molecular subtypes will be assessed mri imaging studies will performed on a 1.5 t scanner , the patient is placed in the prone position with both breasts placed adequately in a double breast coil (four-channel phased array coil), mri sequences are: 1. axial t1wi. 2. axial t2wi. 3. axial stir. 4. dce-mri with post-processing subtraction images 5- axial dwi at b value( 0, 400, 800 and 1000 mm\^2 per second) and adc map will performed 6. mri spectroscopy mri acquisition protocol mri protocols includes * axial t2-weighted fast spin echo sequence: tr=3840 ms, te=81 ms, slice thickness=3.5 mm, and matrix=448×448. * coronal t2-weighted fast spin echo sequence: tr=3840 ms, te=81 ms, slice thickness=3.5 mm, and matrix=448×448.s * short tau inversion recovery - axial: tr=8540 ms, te=59 ms, ti=170 ms, slice thickness=3.5 mm, and matrix=320×314.4. * the standard dynamic protocol commenced with a coronal three-dimensional rapid field echo (thrive) sense non-enhanced t1-weighted sequence. * a gadolinium containing contrast was administered at a dose of 0.2 ml/ kg by power injection at a speed of 2.0 ml/s and flushed with 20 ml of saline solution at the same rate. * dynamic imaging was then done in five consecutive series at 90-s intervals. standard subtraction images were obtained by subtracting precontract images from the early peak postcontrast image.

Eligibility criteria:
inclusion criteria: a. patients with breast cancer confirmed by histopathology, exclusion criteria: 1. breast implants 2. general contraindication of mri as claustrophobia
continuous lumbar plexus block with and without parasacral block in patients undergoing total hip replacement

Conditions: Osteoarthritis of Hip; Regional Anesthesia; Other Acute Postoperative Pain; Total Hip Arthroplasty; Peripheral Nerve Block; Lumbar Plexus Nerve Block; Parasacaral (Sciatic) Nerve Block

Summary: the purpose of this research study is to evaluate the analgesic efficacy of adding a single shot parasacral (sciatic) nerve block to a continuous lumbar plexus block in patients undergoing total hip replacement.

this prospective study is intended to assess the efficacy of placing a parasacral (sciatic) nerve block in addition to a lumbar plexus block for postoperative analgesia following total hip arthroplasty. although the placement of a lumbar plexus block alone has become accepted as the standard of care at upmc for postoperative analgesia following total hip arthroplasty, the addition of a parasacral (sciatic) nerve block may provide the advantage of blocking the superior gluteal nerve and nerve to the quadratus femoris which both supply small articular sensory branches to the posterior hip capsule.

Eligibility criteria:
inclusion criteria: 1. subject has signed and dated an informed consent form. 2. subject is classified as a asa (american society of anesthesiologists) status i-iii 3. subject is age 18- 75 years old. 4. subject is having primary total hip arthroplasty 5. no contraindication to peripheral nerve catheter ( local infection or hypocoagulable state) 6. patient willing to receive spinal anesthesia as operative anesthesia 7. no known drug allergies to study medications 8. patients not expected to receive therapeutic anticoagulation in the postoperative period. exclusion criteria: 1. subject inability to provide adequate informed consent. 2. age younger than 18 years or older than 75 years 3. any contraindication to the placement of lumbar plexus catheter, including local infection, hypocoagulable state. 4. asa (american society of anesthesiologists) physical status of iv or greater 5. any chronic painful conditions 6. preoperative opioid use 7. coagulation abnormalities or patients who are expected to be on therapeutic anticoagulants postoperatively

Keywords: peripheral nerve block total hip replacement
to evaluate ezetimibe plus atorvastatin versus atorvastatin in patients with high cholesterol not controlled on atorvastatin 40 mg (0653-090)

Conditions: Hypercholesterolemia

Summary: to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at high risk for coronary heart disease not adequately controlled on atorvastatin 40 mg.


Eligibility criteria:
inclusion criteria: * patient with ldl-c \>70 mg/dl \& on a stable dose of atorvastatin 40 mg exclusion criteria: * pregnant or lactating women or intending to become pregnant * patient with sensitivity or intolerance to ezetimibe or atorvastatin
transcutaneous sensors for the detection of cancer-related lymphedema, project limb rescue study

Conditions: Hematopoietic and Lymphoid System Neoplasm; Lymphedema; Malignant Solid Neoplasm

Summary: this clinical trial studies how well new adhesive-based sensors that stick to the skin (transcutaneous) work in detecting cancer-related long-term arm swelling (lymphedema). for many patients, lymphedema s painful, unsightly, and weakening. the early signs of lymphedema are hard to see, and sometimes it is only diagnosed by hospital equipment at larger centers. treating lymphedema early is usually more successful than trying to treat in later stages. the adhesive-based sensors used in this study work by using techniques called photoplethysmography (ppg) and bioimpedance (bi). ppg is an optical technique that can be used to detect blood volume changes in tissue. bi evaluates how tissue responds to an externally applied electrical current. this study may assist researchers in distinguishing participants with lymphedema in comparison to participants without lymphedema, and develop a way for patients to check for lymphedema at home.

primary objective: i. describe a unique signature using a combination of photoplethysmography and bioimpedance that distinguishes participants with lymphedema in comparison to participants without lymphedema at rest. secondary objectives: i. in participants with lymphedema, describe a unique signature using a combination of photoplethysmography and bioimpedance that distinguishes the affected arm in comparison to the unaffected arm. ii. tolerability of the transcutaneous sensors during the participant data collection session. iii. use a combination of photoplethysmography and bioimpedance to identify likely cut points for lymphedema in participants with lymphedema. outline: participants undergo bi and wear "watch-like" sensors and undergo ppg at rest and while active (pedaling an exercise bike) on study.

Eligibility criteria:
inclusion criteria: * cohort a: healthy participants * cohort b: participants with pre-existing lymphedema * cohort b: a history of cancer therapy with surgery or radiation involving the axillary basin * cohort b: unilateral upper extremity swelling that requires compression or pneumatic therapy or a \>= 2-centimeter difference in contralateral arm circumference exclusion criteria: * patients with active malignancy or ongoing cancer therapy will be excluded, though breast cancer patients currently on endocrine monotherapy will be included
the hellenic thoracic society initiative for cοpd and cvd

Conditions: Chronic Obstructive Pulmonary Disease (COPD); Cardiovascular Diseases (CVD)

Summary: copd is one of the most common respiratory diseases in greece, and maybe more than half a million greek citizens suffer both from copd and cvd, however their characteristics and management remain unknown. helicopd is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the copd- and cvd-related adverse events in a two-years period, their quality of life and the healthcare resources use. the study is initiated and coordinated by the hellenic thoracic society.


Eligibility criteria:
inclusion criteria patients should cumulatively meet the following three (3) criteria to be enrolled in the study: 1. to have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial fibrillation, severe valvular disease) 2. adults aged \&gt;35 years at the time of inclusion in the study, 3. with signed informed consent for their participation in the study. exclusion criteria patients with the below limitations are not eligible to participate in the study patients: 1. without at least one cardiovascular comorbidity, 2. with history of lung cancer 3. with any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy) 4. with any thoracic or abdominal surgery planned during study follow-up period 5. with participation in any copd-related interventional study at study entry or during study duration. 6. without signed informed consent for their participation in the study.

Keywords: chronic obstructive pulmonary disease copd cardiovascular disease cvd protocol real-world data
medulloblastoma online video-based exercise pilot study

Conditions: Medulloblastoma, Childhood

Summary: in this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma. the exercise sessions will be individualized and offered three times weekly during 12 weeks.

tumors of the central nervous system (cns) represent 25-30% of all cases of pediatric cancer in sweden. the survival for children with a brain tumor has improved over the last years. the 5-year overall survival rate is now 70%, resulting in a growing number or survivors every year. malignant brain tumors typically have a poor prognosis, and curative treatment usually requires a combination of neurosurgery, chemotherapy and/or radiotherapy. for the survivors, the cure often comes at the cost of long-term side effects. finding effective ways to mitigate the long-term side effects after childhood brain tumor is important, since they can severely impact the survivors´ daily life. there is growing evidence that physical exercise is beneficial to cognition and improves cardiorespiratory fitness and motor function. it appears to be important that interventions start early, within 1-2 years after radiotherapy. for this to be feasible in international multicenter trials, the intervention and outcome assessments will need to be delivered remotely. whether this is feasible in children treated for medulloblastoma is not known. the investigators will perform a pilot study to provide pivotal information on whether exercise training can be remotely delivered in the home environment in children treated for medulloblastoma. this will take exercise training from an interesting research concept into a scalable intervention that can be offered regardless of geographic location of the patient. the study will further define the validity and feasibility of in-home outcome assessments of cardiorespiratory, muscular fitness and motor function in children treated for medulloblastoma. if shown feasible, this will work as a proof-of-concept and lead the way for including physical activity intervention in other childhood cancer treatment protocols as well. the results from this study will also enable the researchers to proceed in the planning of the first exercise intervention to be included upfront in an international childhood cancer treatment protocol, the upcoming pan-european treatment protocol for standard-risk medulloblastoma in children (siop-mb6).

Eligibility criteria:
inclusion criteria: completed therapy for medulloblastoma, including craniospinal radiation therapy, within 36 months before study entry. - exclusion criteria: inability to walk without support. progressive disease. -

Keywords: exercise rehabilitation medulloblastoma
tocolytics trial: intravenous (iv) magnesium versus oral nifedpine in fetal fibronectin (ffn) postive population

Conditions: Labor, Premature

Summary: in women with singleton gestations, to contemporarily assess the efficacy of oral nifedipine versus intravenous magnesium sulfate in the acute management of preterm labor in terms of defined early and late neonatal measures


Eligibility criteria:
inclusion criteria: * patients between 240/7-320/7 weeks gestation with findings consistent with preterm labor defined by at least one of the following criteria in accordance with regular uterine contractions (\>4 uterine contractions in 20 minutes): 1. cervix \> 2 cm in dilation or 80% effaced 2. positive fetal fibronectin (if performed). 3. demonstrated cervical change between two exams within 90 minutes. exclusion criteria: * negative fetal fibronectin * \> 5cm dilatation * multiple gestations * known fetal anomalies or chromosomal abnormalities * ruptured membranes * significant vaginal bleeding * suspected chorioamnionitis * preeclampsia or uncontrolled hypertension * non-reassuring fetal heart tracing * placenta previa and/or accreta * placenta abruption * intrauterine growth restriction * maternal renal disease * underlying maternal cardiac condition * symptomatic hyperthyroidism * significant maternal disease * contraindication to nifedipine or magnesium * cerclage presence * tocolytic use within the last 12 hours * hypotension (defined as average blood pressure of \<70/40's unresponsive to 1000 cc fluid bolus

Keywords: composite early neonatal outcome late neurological neonatal outcome
maintenance study on the long term safety of xl999

Conditions: Advanced Malignancies

Summary: the primary objective of this study is to allow rollover of the two remaining subjects from the other xl999 studies to continue to receive xl999. the secondary objectives of this study are as follows: * to evaluate tumor response after long term repeat administration of xl999 in two subjects rolled over from other xl999 studies. * to characterize the long term safety and tolerability of xl999 after repeat administration in two subjects rolled over from other xl999 studies. * to characterize the long term effects of xl999 on cardiac function after repeat administration in two subjects rolled over from other xl999 studies.


Eligibility criteria:
inclusion criteria: * the subject is currently enrolled in protocols xl999-001 or xl999-204 * the subject has received xl999 for at least one year prior to enrollment * per the respective parent xl999 protocol, the subject is eligible to continue to receive xl999 in the absence of progressive disease (pd) or unacceptable drug-related toxicity exclusion criteria: * progressive disease * any development(s) that would meet the exclusion criteria from the subject's respective xl999 protocol (xl999-001 or xl999-204)
study to assess pxl770 in subjects with adrenomyeloneuropathy (amn) form of x-linked adrenoleukodystrophy (x-ald or ald)

Conditions: Adrenomyeloneuropathy

Summary: a randomized open-label phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of pxl770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (amn).

a randomized open-label phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of pxl770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (amn). there are 3 study periods. * screening visit: within a maximum of 4 weeks prior to the open-label treatment period * open-label treatment period: 12 weeks * follow-up period: 2 weeks after the last intake of the treatment during the treatment period, vlcfa will be assessed every 4 weeks, to evaluate the kinetics of the effect. nfl will be assessed after 8 and 12 weeks of treatment, and other exploratory biomarkers after 12 weeks of treatment. a follow up period will allow monitoring the subjects' safety as well as the duration of the effect on the 2 main biomarkers (vlcfa and nfl) at 2 and 4 weeks after the drug withdrawal.

Eligibility criteria:
inclusion criteria: * male subjects with either a confirmed diagnosis of amn by genetic testing (mutation in the atp binding cassette subfamily d (abcd1 gene)) or a family history of x-linked adrenoleukodystrophy (ald) together with an elevation in vlcfa obtained from overnight fasting plasma sample at screening visit (v1). * age: ≥ 18 to ≤ 65 years at informed consent signature. * normal brain magnetic resonance imaging (mri) or brain mri showing non-specific abnormalities that can be observed in amn subjects without signs of cerebral form of ald (c-ald). mri must be performed within 6 months prior to v2. if there is no available brain mri within this period, a brain mri must be performed before v2. exclusion criteria: * any progressive neurological disease other than amn. * arrested or progressing c-ald as defined by cerebral lesions (except for non-specific abnormalities that can be observed in amn subjects). * prior receipt of an allogeneic hematopoietic stem cell transplant or gene therapy.
correlation endoscopic view of airway obstruction with rra in osa patients under dex monitored with sedline eeg

Conditions: Obstructive Sleep Apnea (OSA)

Summary: patients with obstructive sleep apnea (osa) could have several anatomical causes of obstruction. a sleep endoscopy study is a technique to help determine the anatomical cause of osa. this study will be using standard of care practice and infuse dexmedetomidine (dex) to induce sleep. the goals of the study are to (1) confirm airway obstruction with endoscopic view and correlate that with acoustic respiratory rate (rra) signal at the moment of airway obstruction, and (2) characterize the eeg signals when subjects are under dex sedation alone.


Eligibility criteria:
inclusion criteria: * adult patients more than 18 years old with american society of anesthesiologists (asa) classification of i, ii, or iii. * patients undergoing sedation for sleep endoscopy with dex alone, and possible surgical follow-up. exclusion criteria: * asa classification higher than iii. * any deformities or diseases that may prevent application of sedline (masimo sedation monitoring) or ram (masimo rainbow acoustic monitoring) sensors with a proper fit * inability to obtain any physiological, vital, demographics and real time anaesthesia data * subjects who have known intolerance to any of the drugs to be used according to the study protocol * subjects deemed not suitable for study at the discretion of the principal investigator.